Patent · US Active

Bacteria engineered to reduce hyperphenylalaninemia

US9943555B2 · kind B2 · utility

4Cited by
5References
14Claims
0Family size

Assignee

Inventors

Key dates

Filing dateSep 8, 2016
Grant dateApr 17, 2018
Priority date
Expiry dateSep 8, 2036

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY02A50/30
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.